Phase 1, single-arm, open-label, dose escalation trial of microneedle array-doxorubicin in patients with mycosis fungoides

Citations Over Time

Related Papers

• → Naringenin Enhances the Anti-Tumor Effect of Doxorubicin Through Selectively Inhibiting the Activity of Multidrug Resistance-Associated Proteins but not P-glycoprotein(2008)87 cited
• → Protectors against doxorubicin-induced cardiotoxicity: Flavonoids(2006)62 cited
• Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin.(1997)
• Clinical Study of Kangai Injection Combined with Chemotherapy in the Treatment of Advanced Lung Cancer(2009)
• Breast Cancer Surgery Kangai Injection Chemotherapy Combined Application of the Clinical Curative Effect(2012)